On September 28, 2016 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) reported it will present six posters from its systems-biology derived antibody engineering and nanotherapeutic portfolios at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2016 Congress, October 7 – 11, 2016 in Copenhagen, Denmark (Press release, Merrimack, SEP 28, 2016, View Source [SID:SID1234515489]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Merrimack will present the final results of the Phase 3 NAPOLI-1 study in a poster discussion session and a NAPOLI-1 safety-over-time subset analysis in a separate poster session. The primary Phase 3 NAPOLI-1 data were the basis of the US Food and Drug Administration (FDA) and Taiwan FDA approvals of the ONIVYDE (irinotecan liposome injection) combination regimen in October 2015. It is also the basis of the European Union’s Committee for Medicinal Products for Human Use (CHMP) positive opinion issued in July 2016.

Additional ESMO (Free ESMO Whitepaper) 2016 poster presentations include an evaluation of MM-302’s potential for treating HER2-intermediate tumors as well as two trials-in-progress posters, both potentially registrational, for MM-302 and seribantumab, also known as MM-121. MM-302 is an investigational HER2-targeted liposomal encapsulation of doxorubicin from Merrimack’s antibody-directed nanotherapeutic platform, while seribantumab is Merrimack’s investigational anti-ErbB3 monoclonal antibody that targets heregulin-positive cancer cells within solid tumors.

Poster Discussion Session:

Final results of NAPOLI-1: A Phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy (Abstract 622PD)
Session Title: Gastrointestinal tumours, non-colorectal
Date/Time: October 8, 2016, 8:40 am – 8:50 am (CEST)
Location: Copenhagen
Poster Sessions:

Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A Phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy (Abstract 693)
Session Title: Gastrointestinal tumours, non-colorectal
Date/Time: October 8, 2016, 1:00 pm – 2:00 pm (CEST)
Location: Hall E

Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors (Abstract 1560)
Session Title: Translational research
Date/Time: October 10, 2016, 1:00 pm – 2:00 pm (CEST)
Location: Hall E

HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1 (Abstract 315TIP)
Session Title: Breast cancer, locally advanced and metastatic
Date/Time: October 10, 2016, 1:00 pm – 2:00 pm (CEST)
Location: Hall E

SHERLOC: A Phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC) (Abstract 1296TIP)
Session Title: NSCLC, metastatic
Date/Time: October 8, 2016, 1:00 pm – 2:00 pm (CEST)
Location: Hall E